B.A. ABUSUEVA¹, M.A. EVZELMAN², P.R. KAMCHATNOV³, Kh.Ya. UMAROVA⁴

¹Dagestan State Medical Academy, 1 Lenin Square, Makhachkala, Russian Federation, 367000

² Medical Institute of Orel State University, 25 Oktyabrskaya Str., Orel, Russian Federation, 302028

³ Russian National Research Medical University named after N.I. Pirogov, 1 Ostrovityanova Str., Moscow, Russian Federation, 117997

⁴Chechen State University, 32 Sheripov Str., Grozny, Russian Federation, 364093

Abusueva B.A. ― Cand. Med. Sc., Associate Professor, Head of the Department of Nervous Diseases, Neurosurgery and Medical Genetics

Evzelman M.A. ― D. Med. Sc., Professor of the Department of Psychiatry and Neurology

Kamchatnov P.R. ― D. Med. Sc., Professor of the Department of Neurology, Neurosurgery and Medical Genetics

Umarova Kh.Ya. ― D. Med. Sc., Professor of the Department of Hospital Therapy with courses Outpatient Therapy, Propedeutics in Internal Diseases, general treatment of patients

Chronic ischemia of brain is a widely spread type of cerebral-vascular pathology, and its presence is connected with the increased risk of both the acute ischemic stroke and the lasting neurologic deficit, first of all, cognitive disorders. Correction of the factors of cardio-vascular risk can slow down the progress of vascular lesion of brain, while maintenance of cognitive functions requires other therapeutic approaches. The authors consider the possibilities of using the new Russian drug Cellex in patients with moderate cognitive disorders in chronic ischemia of brain.

Key words: chronic ischemia of brain, moderate cognitive disorders, therapy, Cellex.